ALKERMES | ALKS - Operating Profit


ALKERMES reported $-48.28M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
ALKERMES USD -48.28M 37.33M Mar/2026
Amgen USD 3.83B 130M Mar/2026
Biogen USD 514.3M 128.8M Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -118M 97M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Malin Corporation EUR -1.1M 400K Dec/2024
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Otsuka Holdings JPY 118.21B 50.97B Mar/2026
Ovoca Bio EUR -1.16M 4.48M Jun/2025
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026